RE:RE:Pfizer's Trillium & GBT M&A deals not the last Interestingly, Pfizer didn’t proactively seek a Global Blood Therapeutics (GBT) acquisition in the first place given the significant risk associated with the development of a sickle cell drug.
The first contact with GBT was made by another company, which on May 26 asked to buy out the sickle cell disease (SCD) specialist for $55 per share, the securities filing show. In the months that followed, GBT pitted that first comer and Pfizer against each other, managing to push Pfizer to sweeten its offer several times before agreeing on the $68.50-per-share price in their $5.4 billion deal.
In December 2021, Pfizer aquired the late stage development company Arena Pharmaceuticals for US$ 6.7 Billion in cash (US$100/share) which was developing a treatment candidate that targets inflammatory bowl diseases of the stomach and intestine.